In Bulgarian In Albanian In Macedonian In Romanian In Serbian
The medical isotope Lutetium-177 (Lu-177), which is used in the treatment of various types of cancer, including prostate cancer, will be produced at the nuclear power plant in Cernavooda, Romania, BalkanEngineer.com has learned from mediafax.ro. The project is part of a joint collaboration between the company Nuclearelectrica and the French company Framatome, an international leader in nuclear energy, which conducted a feasibility study and confirmed the possibility of producing this key isotope.
The project involves adapting Framatome's technology to irradiate Iterbium-176, which becomes Lu-177. The process will be carried out in Unit 2 of the plant, with planned commercial operation expected to begin in 2028. This isotope is particularly effective in targeted radionuclide therapy, which destroys cancer cells while keeping healthy tissue intact.
The production of Lu-177 will provide significant benefits for cancer treatment in Romania, while also contributing to the creation of a stable and large-scale supply system for radioisotopes. This system will address the growing demand for medical isotopes in Europe.
Source of the image: ©Enginner.BG via Canva